Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group. Ferguson P, et al. Among authors: kjeldsen l. Haematologica. 2016 Nov;101(11):1351-1358. doi: 10.3324/haematol.2016.148825. Epub 2016 Aug 18. Haematologica. 2016. PMID: 27540133 Free PMC article.
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
Burnett AK, Das Gupta E, Knapper S, Khwaja A, Sweeney M, Kjeldsen L, Hawkins T, Betteridge SE, Cahalin P, Clark RE, Hills RK, Russell NH; UK NCRI AML Study Group. Burnett AK, et al. Among authors: kjeldsen l. Haematologica. 2018 Oct;103(10):1654-1661. doi: 10.3324/haematol.2018.189514. Epub 2018 Jul 5. Haematologica. 2018. PMID: 29976746 Free PMC article. Clinical Trial.
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
Russell NH, Hills RK, Thomas A, Thomas I, Kjeldsen L, Dennis M, Craddock C, Freeman S, Clark RE, Burnett AK. Russell NH, et al. Among authors: kjeldsen l. Haematologica. 2022 Jul 1;107(7):1518-1527. doi: 10.3324/haematol.2021.279010. Haematologica. 2022. PMID: 34647442 Free PMC article. Clinical Trial.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group. Burnett AK, et al. Among authors: kjeldsen l. Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1. Blood. 2015. PMID: 25833957 Free PMC article. Clinical Trial.
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Burnett AK, Russell NH, Hills RK, Knapper S, Freeman S, Huntly B, Clark RE, Thomas IF, Kjeldsen L, McMullin MF, Drummond M, Kell J, Spearing R. Burnett AK, et al. Among authors: kjeldsen l. J Clin Oncol. 2021 Mar 10;39(8):890-901. doi: 10.1200/JCO.20.01170. Epub 2020 Dec 23. J Clin Oncol. 2021. PMID: 33356418 Free PMC article. Clinical Trial.
170 results